Side-by-side · Research reference

CartalaxvsRetatrutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BPhase 2HUMAN-REVIEWED10/41 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

Retatrutide

Triple-receptor agonist · Phase 3

1–12 mgWeekly doseJastreboff 2023

24.2%Body-weight ↓Jastreboff 2023

~6 daysHalf-life (est)

SQ · Abdomen · Once weekly

01Mechanism of Action

Parameter

Cartalax

Retatrutide

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023

Feedback intact?

—

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023

Antibody development

—

02Dosage Protocols

Parameter

Cartalax

Retatrutide

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

Phase 2 trial; Phase 3 ongoingJastreboff 2023

Standard dose

—

12 mg / week (max efficacy)Jastreboff 2023

Phase 2 trial dose. Phase 3 dosing TBD.

Frequency

—

Once weekly

Titration schedule

—

2 mg → 4 mg → 8 mg → 12 mg over 16 weeks

Duration

—

Indefinite for chronic indication (presumed)

Reconstitution

—

Investigational; not commercially available

Timing

—

Any time of day

Half-life

—

~6 days (estimated from class)

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

Retatrutide

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

04Side Effects & Safety

Parameter

Cartalax

Retatrutide

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

—

GI symptoms

—

Nausea, vomiting, diarrhea (very common, dose-dependent)Jastreboff 2023

Heart rate

—

↑ resting HR (3–7 bpm at 12 mg)Jastreboff 2023

Glucose handling

—

Glycemic improvement; rare hyperglycemia from glucagon component

Pancreatitis risk

—

Class warning

Thyroid C-cell tumours

—

Class warning (presumed)

Pregnancy / OB

—

Avoid (insufficient data)

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

Retatrutide

·MTC personal or family history (presumed class effect)
·Pregnancy / breastfeeding

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

Retatrutide

·Severe gastroparesis
·History of pancreatitis
·Severe cardiovascular disease (HR signal)

05Administration Protocol

Parameter

Cartalax

Retatrutide

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Investigational peptide. Research vials reconstituted with bacteriostatic water per label.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

Once weekly, same day.

4. Storage

—

Refrigerate 2–8 °C. Light-protected.

5. Needle

—

27–31G, 4–8 mm insulin syringe.